UroGen Pharma Ltd. — Director's Dealing 2019

Mar 22, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2019-03-21

Reporting Person: Schoenberg Mark (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-21	Ordinary Shares	P	272	$37.009	Acquired	4610	Direct

Footnotes

F1: The reporting person's purchase of Ordinary Shares of the Issuer reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the reporting person's sale of 272 Ordinary Shares of the Issuer at a price of $37.30 per share on March 6, 2019. The reporting person has agreed to pay to the Issuer $79.15, representing the full amount of the profit realized in connection with the short-swing transaction.